Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
-quality teaching. The Hub for Applied Bioinformatics (HAB) is the Faculty’s focal point for computational biology, delivering bespoke bioinformatics support and training across genomics, transcriptomics
-
environment for the pursuit of cutting-edge cardiovascular and metabolic research. We study the fundamental molecular, cellular, and physiological processes that underly normal and abnormal cardiovascular and
-
by Professor Tim Tree, at King's College London. Our team focuses on understanding the immune system's role in autoimmune and inflammatory diseases and exploring immunotherapy to treat them
-
research. We study the fundamental molecular, cellular, and physiological processes that underly normal and abnormal cardiovascular and metabolic function and drive the translation of this strong basic
-
and high-quality teaching. Dr. Alessandra Vigilante leads a research group of bioinformaticians with expertise in multi-omics data integration and translational bioinformatics. She is Head of the Hub
-
cancer organoids from Black male patients. The project will seek to characterise the viability of organoids in response to standard of care chemotherapy and novel agents. In parallel the project will seek
-
strengths in laboratory-based enquiry using molecular genetics, metagenomics, biochemistry, cell biology, bioinformatics and structural biology, with rich clinical resources in microbiology, virology
-
of human infections. Our research bridges our strengths in laboratory-based enquiry using molecular genetics, metagenomics, biochemistry, cell biology, bioinformatics and structural biology, with rich
-
mechanisms, diagnosis and treatment of human infections. Our research bridges our strengths in laboratory-based enquiry using molecular genetics, metagenomics, biochemistry, cell biology, bioinformatics and
-
inflammatory diseases and exploring immunotherapy to treat them. This exciting project involves characterising samples from a recently completed Phase II clinical trial for amyotrophic lateral sclerosis (ALS